Since 2010, Cells for Cells has developed a diverse portfolio of bioengineered implants and advanced therapies for the treatment of high-impact degenerative, autoimmune and chronic diseases, as well as biotools and devices that offer solutions to the industry’s challenges.
According to a recent ISCT paper, it is the most significant driver of CGT investment for specialized capitalists. With eight clinical trials and several more in the pipeline, Cells for Cells’ value proposition is supported by robust preclinical and clinical data.
Our competitive edge is perpetuated through a well-established IP strategy. International patents protect our products and methods, which can be out-licensed via exclusive and non-exclusive partnerships.
We study and comprehend the gaps in the clinic and our industry, as well as the limitations of existing treatments. This deep knowledge guide the design of Cells for Cells’ novel technologies that seek to overcome them.
High-burden and high-growth diseases represent a unique opportunity for biotechs. By offering a solution to these challenges, our products could generate important benefits not only for patients but also for investors.
We seek to create technologies that can be applied not for a single but many medical indications. Our strategy is to patent these technologies and pursue applications coupled with attractive markets.
Cells for Cells has innovated in the manufacturing and scalability of its products, for instance, in the development of a cryopreserved, ready-to-use version of Cellistem®OA and a vascular graft biofabricated in just one hour.
Design&Develop by Tactech
